Surfactant Treatment Compared to Nasal Continuous Positive Airway Pressure for the Management of Respiratory Distress Syndrome in the Newborn Between 35 and 41 Weeks of Gestation

Trial Profile

Surfactant Treatment Compared to Nasal Continuous Positive Airway Pressure for the Management of Respiratory Distress Syndrome in the Newborn Between 35 and 41 Weeks of Gestation

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 May 2016

At a glance

  • Drugs Poractant alfa (Primary)
  • Indications Respiratory distress syndrome
  • Focus Therapeutic Use
  • Acronyms ASPEN
  • Most Recent Events

    • 11 May 2016 Status changed from recruiting to discontinued due to recruiting problems.
    • 26 Sep 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 08 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top